Model-free dynamic contrast-enhanced MRI analysis: differentiation between active tumor and necrotic tissue in patients with glioblastoma

MAGMA. 2023 Feb;36(1):33-42. doi: 10.1007/s10334-022-01045-z. Epub 2022 Oct 26.

Abstract

Objective: Treatment response assessment in patients with high-grade gliomas (HGG) is heavily dependent on changes in lesion size on MRI. However, in conventional MRI, treatment-related changes can appear as enhancing tissue, with similar presentation to that of active tumor tissue. We propose a model-free data-driven method for differentiation between these tissues, based on dynamic contrast-enhanced (DCE) MRI.

Materials and methods: The study included a total of 66 scans of patients with glioblastoma. Of these, 48 were acquired from 1 MRI vendor and 18 scans were acquired from a different MRI vendor and used as test data. Of the 48, 24 scans had biopsy results. Analysis included semi-automatic arterial input function (AIF) extraction, direct DCE pharmacokinetic-like feature extraction, and unsupervised clustering of the two tissue types. Validation was performed via (a) comparison to biopsy result (b) correlation to literature-based DCE curves for each tissue type, and (c) comparison to clinical outcome.

Results: Consistency between the model prediction and biopsy results was found in 20/24 cases. An average correlation of 82% for active tumor and 90% for treatment-related changes was found between the predicted component and population-based templates. An agreement between the predicted results and radiologist's assessment, based on RANO criteria, was found in 11/12 cases.

Conclusion: The proposed method could serve as a non-invasive method for differentiation between lesion tissue and treatment-related changes.

Keywords: Classification; DCE; Glioblastoma; MRI; Treatment response assessment.

MeSH terms

  • Algorithms
  • Contrast Media
  • Glioblastoma* / diagnostic imaging
  • Glioma*
  • Humans
  • Magnetic Resonance Imaging / methods

Substances

  • Contrast Media